OakChart

AnaptysBio Inc

ANABHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 9:44 AM ET

48.58+0.20 (0.41%)
2026-11-11 15:44 CET
Market cap
1,446.33 USD m
Revenue, TTM
237.61 USD m
Net income, TTM
195.72 USD m
Free cash flow, TTM
18.07 USD m
EPS diluted, TTM
6.45
P/E
7.54
Compare

Price

ANAB against its 20, 50 and 200-day averages
2050200earnings
30.0040.0050.0060.0070.00772K1.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ANABclose 48.5820-day 47.9850-day 50.17200-day 51.0448.58

32.9% under 72.36 on 5 May 2026. Last 15 sessions, 13.8% high to low

Profile

ANAB
52-week range, 53% of the way up
21.4672.36

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm's product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

IndexRUT
Employees104
IPOJan 26, 2017
Beta0.86
ATR, 14d2.07
Rel volume0.35
Short float18.09%
Insider own6.62%
Inst own103.90%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.45B
Enterprise Value1.56B
Income195.72M
Sales237.61M
Book/sh0.36
Cash/sh5.49
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees104
IPOJan 26, 2017

Ratios

P/E7.54
Forward P/E-
PEG-
P/S6.11
P/B136.44
P/C8.85
P/FCF80.37
EV/EBITDA11.44
EV/Sales6.56
Quick Ratio5.61
Current Ratio5.61
Debt/Eq25.46
LT Debt/Eq25.25
Option/ShortYes / Yes

Earnings

EPS (ttm)6.45
EPS next Y-
EPS next Q0.85
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y53.48% 8.82%
Sales past 3/5Y183.58% 25.62%
EPS Y/Y TTM249.01%
Sales Y/Y TTM92.92%
EPS Q/Q561.29%
Sales Q/Q23.47%
EarningsSep 21 AMC
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own6.62%
Insider Trans-0.25%
Inst Own103.90%
Inst Trans4.15%
ROA70.78%
ROE-114.55%
ROIC70.40%
Gross Margin96.78%
Oper. Margin56.36%
Profit Margin82.37%
SMA201.24%
SMA50-3.17%
SMA200-4.83%
Trades-

Technical

Shs Outstand29.73M
Shs Float27.92M
Short Float18.09%
Short Ratio10.57
Short Interest5.05M
52W High72.36 -32.86%
52W Low21.46 126.34%
Volatility4.68% 4.72%
ATR (14)2.07
RSI (14)50.52
Beta0.86
Rel Volume0.35
Avg Volume477.71K
Volume13,877

Performance

Perf Week2.25%
Perf Month6.56%
Perf Quarter-13.28%
Perf Half Y-22.50%
Perf YTD50.33%
Perf Year117.17%
Perf 3Y409.66%
Perf 5Y119.12%
Perf 10Y-
Recom1.14
Target Price79.71
Prev Close48.38
Price48.58
Change %0.41%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 10, 2026ResumedHH.C. WainwrightBuy$95+95.6%
Jan 07, 2026ResumedUUBSBuy$70+44.1%
Oct 13, 2025InitiatedBBarclaysOverweight$78+60.6%
Jun 04, 2025UpgradeHH.C. WainwrightNeutral → Buy$38-21.8%
Feb 04, 2025InitiatedWWolfe ResearchOutperform$25-48.5%
Dec 11, 2024DowngradeHH.C. WainwrightBuy → Neutral$52 → $19-60.9%
Dec 02, 2024DowngradeBBTIG ResearchBuy → Neutral
Jul 22, 2024InitiatedHH.C. WainwrightBuy$55+13.2%
Jul 19, 2024UpgradeJJP MorganNeutral → Overweight$29 → $69+42.0%
Apr 16, 2024InitiatedLLeerink PartnersOutperform$47-3.3%

Peers

Mkt cap
TickerCompanyMkt cap
RPRXRoyalty Pharma plc39.94B
INVAInnoviva Inc1.34B
LGNDLigand Pharmaceuticals Inc6.32B
HALOHalozyme Therapeutics Inc11.37B
TRAXFirst Tracks Biotherapeutics Inc2.19B
OABIOmniAb Inc741.70M
ABCLAbCellera Biologics Inc4.11B
GSKGSK Plc ADR100.85B
REGNRegeneron Pharmaceuticals Inc93.68B
MRKMerck & Co Inc361.79B

Insider trading

latest 14 of 88
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RENTON HOLLINGSDirectorOct 01 '26Option Exercise18.035,00090,15015,995Oct 02 05:47 PM
RENTON HOLLINGSDirectorOct 01 '26Sale49.875,000249,37210,995Oct 02 05:47 PM
HOLLINGS C RENTONDirectorOct 01 '26Proposed Sale49.875,000249,372Oct 01 04:07 PM
Orwin John ADirectorSep 15 '26Option Exercise0.001,300017,995Sep 17 04:05 PM
JOE ANTHONY WAREDirectorJul 13 '26Proposed Sale67.1710,694718,333Jul 13 04:12 PM
JOE ANTHONY WAREDirectorJun 30 '26Proposed Sale67.796,030408,774Jun 30 04:04 PM
DENNIS MULROYOfficerJun 29 '26Proposed Sale63.459,476601,213Jun 29 04:15 PM
DENNIS MULROYOfficerJun 26 '26Proposed Sale60.8210,000608,183Jun 26 04:46 PM
DENNIS MULROYOfficerJun 17 '26Proposed Sale60.0085051,000Jun 17 04:29 PM
Schmid John P.DirectorJun 15 '26Option Exercise0.006,030037,652Jun 17 04:05 PM
RENTON HOLLINGSDirectorJun 15 '26Option Exercise0.006,030010,995Jun 17 04:05 PM
Orwin John ADirectorJun 15 '26Option Exercise0.006,030016,695Jun 17 04:05 PM
DENNIS MULROYOfficerJun 16 '26Proposed Sale60.001,26575,900Jun 16 05:28 PM
DENNIS MULROYOfficerJun 15 '26Proposed Sale57.6520,0001,153,014Jun 15 05:47 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
PBEInvesco Biotechnology & Genome ETFAUM: 438.02M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • Anaptys Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
  • Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer (GlobeNewswire) +5.64%
  • Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Loading…
  • Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors (GlobeNewswire)
  • Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference (GlobeNewswire)
  • Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence (PR Newswire) -5.70%
  • GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio (Proactive) +13.09%
  • Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim (GlobeNewswire) +14.84%
  • Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations (GlobeNewswire) +13.22%
  • First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement (GlobeNewswire) -11.68%
  • Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-09-215.1105.1105.11027.4927.491
2025Q42026-03-031.0530.5751.583108.2587.0412
2025Q32025-11-040.520-1.2140.52176.3221.9211
2026Q22025-08-06-0.893-0.893-0.89322.2622.261
2025Q12025-05-05-1.280-1.253-1.28327.7715.2711
2024Q42025-02-27-0.720-1.619-0.71543.117.7811
2024Q32024-11-05-1.140-1.647-1.13730.028.2112
2024Q22024-08-05-1.710-1.041-1.70610.9722.7611
2024Q12024-05-09-1.640-1.566-1.6397.184.0010
2023Q42024-03-11-1.590-1.601-1.5889.013.799
2023Q32023-11-02-1.410-1.777-1.4053.322.296
2023Q22023-08-07-1.500-1.695-1.4963.462.686
2023Q12023-05-11-1.580-1.032-1.5831.372.906
2022Q42023-03-01-0.930-0.957-0.9296.815.787
2022Q32022-11-08-1.180-0.622-1.1841.2913.438
2022Q22022-08-08-1.150-0.982-1.1541.225.305

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.7300.043-0.73075.0095.00
2021FY-2.110-1.833-2.10763.1863.17
2022FY-4.570-4.526-4.57010.299.05
2023FY-6.080-6.069-6.07717.1611.94
2024FY-3.413-4.056-3.41391.2855.91
2025FY-0.307-0.876-3.413234.6207.28
2026FY--1.930--91.95
2027FY-----
2028FY-----
2029FY-----
2030FY-----
2031FY-----

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2026-10-1653240.1028.8958.51
2027Q1S2026-10-0152228.400.0041.83
2027Q1S2026-09-2252228.400.0041.83
2027Q1S2026-09-0940016.130.0036.62
2027Q1S2026-09-023009.300.0027.89
2027Q1S2026-08-294006.970.0027.89
2027Q1S2026-08-2450014.010.0042.17
2027Q1S2026-08-2340017.510.0042.17
2027Q1S2026-08-2140117.510.0042.17
2027Q1S2026-08-0470122.530.0051.00
2027Q1S2026-07-2770222.530.0051.00
2027Q1S2026-07-1371322.530.0051.00
2027Q1S2026-07-0861326.280.0051.00
2027Q1S2026-07-0161426.280.0051.00

Estimate history

EPS, annual-1.52-2.499-3.597-0.73-2.107-4.57-6.077-5.117-0.466.446
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.706-1.137-0.715-1.283-1.3410.5211.583-1.8436.185
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual10587563.17510.28717.15791.28234.603237.61
Period201720182019202020212022202320242025TTM
Sales, quarterly10.97130.01743.11327.77122.26376.32108.24925.55627.488
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.79126.92227.25527.35627.64728.51326.59730.47328.01929.728
Period201720182019202020212022202320242025MRQ
Shares, quarterly27.43430.42930.47330.38827.97327.57528.01929.03129.728
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue237.61234.6091.2817.1610.2963.1775.008.005.00
Cost of Goods Sold Incl. D&A-2.422.402.382.33----
Gross Profit-232.1888.8814.787.95----
Selling, General and Administrative Excl. Other-184.28203.83171.85123.11117.9098.32114.9271.41
Research and Development-135.41163.23131.6386.4696.4179.4798.8256.20
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income133.9347.90-114.95-157.07-115.15-56.81-23.88-107.43-66.72
Interest Expense83.4279.8950.0918.0821.110.000.001.041.65
Unusual Expense0.000.000.007.34--0.10-0.100.000.00
Net Income Before Taxes59.72-13.07-145.23-163.62-128.70-57.80-19.93-97.49-61.85
Income Taxes-181.370.160.00-0.000.020.000.00-0.15-0.19
Consolidated Net Income241.09-13.23-145.23-163.62-128.72-57.80-19.93-97.34-61.66
Net Income From Continuing Operations241.09-13.23-145.23-163.62-128.72-57.80-19.93-97.34-61.66
Net Income195.72-13.23-145.23-163.62-128.72-57.80-19.93-97.34-61.66
EPS (Recurring)6.58-0.46-5.12-5.89-4.57-2.11-0.73-3.60-2.50
EPS (Basic, Before Extraordinaries)6.67-0.46-5.12-6.08-4.57-2.11-0.73-3.60-2.50
EPS (Diluted)6.45-0.46-5.12-6.08-4.57-2.11-0.73-3.60-2.50
EBITDA136.1150.32-112.55-154.70-112.82-54.72-23.32-106.92-66.41
Non-Operating Income (Expense)9.2118.9319.8118.877.56-1.083.8510.986.53
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-28.5026.9026.2321.61-15.358.399.067.87
Price To Earnings Ratio7.517.51-------
Price To Sales Ratio8.445.944.1233.6184.8515.097.8354.96314.78
Gross Margin-98.9797.3786.1577.30----
Operating Margin56.3620.42-125.93-915.50-1,119.41-89.93-31.84-1,342.90-1,334.44
Net Margin82.37-5.64-159.10-953.66-1,251.33-91.49-26.57-1,216.70-1,233.12
Shares Outstanding29.7328.0230.4726.6028.5127.6527.3627.2626.92
Market Capitalization1,446.331,446.33268.54379.44587.31637.17391.93293.901,137.50

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue27.4925.56108.2576.3222.2627.7743.1130.02
Cost of Goods Sold Incl. D&A-0.610.610.610.600.610.600.60
Gross Profit-24.95107.6475.7121.6627.1642.5129.42
Selling, General and Administrative Excl. Other-59.5840.7441.0147.8354.7052.1852.18
Research and Development-33.8625.4331.2737.6841.0342.4442.07
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income66.96-34.6466.9034.70-26.17-27.54-9.67-22.76
Interest Expense20.3320.8619.7122.5219.6118.0617.4015.41
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes47.75-52.8449.7015.11-38.59-39.28-21.79-32.85
Income Taxes-181.490.040.080.000.040.04-0.010.00
Consolidated Net Income229.24-52.8849.6115.11-38.63-39.33-21.78-32.85
Net Income From Continuing Operations229.24-52.8849.6115.11-38.63-39.33-21.78-32.85
Net Income183.88-52.8849.6115.11-38.63-39.33-21.78-32.85
EPS (Recurring)6.19-1.841.580.52-1.34-1.28-0.72-1.14
EPS (Basic, Before Extraordinaries)6.19-1.841.790.54-1.34-1.28-0.72-1.14
EPS (Diluted)6.19-1.841.580.52-1.34-1.28-0.72-1.14
EBITDA67.32-34.0367.5135.31-25.57-26.93-9.07-22.16
Non-Operating Income (Expense)1.122.652.502.927.186.325.265.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-11.236.727.237.307.246.478.19
Price To Earnings Ratio7.51-------
Price To Sales Ratio8.446.856.485.245.195.094.4216.93
Gross Margin-97.6199.4499.2097.3097.8298.6198.01
Operating Margin243.59-135.5361.8045.47-117.55-99.16-22.43-75.81
Net Margin668.95-206.9345.8319.80-173.52-141.62-50.53-109.44
Shares Outstanding29.7329.0328.0227.5827.9730.3930.4730.43
Market Capitalization1,446.331,062.76894.76571.43434.77380.01268.54674.36

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments311.64385.37390.90441.24548.10393.65374.23427.08248.41
Short Term Receivables33.8540.776.851.420.880.000.000.171.60
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.765.749.084.544.902.913.516.962.69
Total Current Assets350.25431.88406.83447.20553.88396.56377.73434.22252.70
Net Property, Plant & Equipment13.8916.2318.2719.9921.842.133.021.450.67
Total Investments and Advances0.0035.4727.03142.9467.1017.6154.3773.1975.96
Intangible Assets---0.000.000.000.000.000.00
Other Assets0.260.260.260.260.260.260.080.150.05
Total Assets364.39483.83452.39610.38643.07416.55435.20509.00329.36
Short Term Debt Incl. Current Port. of LT Debt2.081.931.781.641.500.342.257.576.88
Accounts Payable3.874.004.702.781.744.2216.245.442.32
Other Current Liabilities32.6739.5030.9721.6312.8515.2611.058.824.89
Total Current Liabilities38.6245.4337.4426.0516.1019.8229.5421.8414.09
Long Term Debt288.56367.54326.84322.2319.450.000.650.627.55
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.00251.090.000.000.170.14
Total Liabilities327.19412.97364.29348.28286.6419.8230.1922.6321.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity37.2170.8788.10262.10356.43396.73405.01486.37307.58
Total Shareholders Equity37.2170.8788.10262.10356.43396.73405.01486.37307.58
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity37.2170.8788.10262.10356.43396.73405.01486.37307.58
Total Liabilities & Stockholders Equity364.39483.83452.39610.38643.07416.55435.20509.00329.36
Book Value Per Share1.332.333.319.1912.8914.5014.8618.0712.93
Tangible Book Value Per Share1.332.333.319.1912.8914.5014.8618.0712.93
Full-Time Employees1041361179610294897860
Price to Book Ratio135.883.183.152.111.800.990.732.3513.58
Return on Assets-3.12-31.02-30.79-20.54-10.91-4.68-20.62-14.71-15.36
Return on Equity-24.49-182.71-93.44-41.62-15.35-4.97-21.84-15.53-17.34
Return on Invested Capital-4.06-33.13-39.43-22.03-15.38-5.02-23.99-12.66-9.54
Quick Ratio9.079.5110.8717.1634.4020.0112.7919.8917.93
Current Ratio9.079.5110.8717.1634.4020.0112.7919.8917.93

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income286.45-13.23-145.23-163.62-128.72-57.80-19.93-97.34-61.66
Depreciation2.182.422.402.382.332.090.560.510.32
Other Funds (Non Cash)11.44111.2373.7240.7245.9617.2711.9910.459.37
Funds from Operations116.37100.42-69.11-120.52-80.43-38.43-7.39-86.37-51.97
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-98.29-80.72-66.33-0.326.84-7.49-6.7716.853.46
Income Taxes Payable------0.000.000.14
Cash from Operating Activities18.0819.70-135.44-120.84-73.59-45.92-14.16-69.52-48.51
Capital Expenditures-0.01-0.09-0.36-0.81-0.36-1.37-0.57-0.81-1.06
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.010.000.000.00
Purchase or Sale of Investments219.34228.1295.76145.56-394.4940.1995.04132.24-141.39
Purchase of Investments-24.61-196.41-380.38-303.92-802.50-118.66-194.93-251.81-347.54
Sale Or Maturity of Investments243.95424.53476.13449.48408.02158.85289.97384.05206.15
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities219.33228.0395.40144.75-394.8538.8494.47131.43-142.45
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock24.82-54.3799.89-47.5311.832.550.503.01230.24
Repurchase of Common Pref Stock-13.10-68.63-0.46-50.000.000.000.000.000.00
Sale of Common Pref Stock37.9214.26100.352.4711.832.550.503.01230.24
Proceedsfrom Stock Options37.9214.26100.352.4711.832.550.000.00227.29
Issuance or Reduction of Debt, Net-72.70-76.8034.77-11.7332.190.00-1.38-7.50-6.88
Change in Long Term Debt-72.70-76.8034.77-11.7332.190.000.000.000.00
Issuance of Long Term Debt0.000.0050.000.0034.660.000.000.000.00
Reduction of Long Term Debt-72.70-76.80-15.23-11.73-2.470.000.000.000.00
Net Financing Active Other Cash Flow-100.00-1.45-7.500.000.00249.750.000.000.00
Other Financing Activities Uses-100.00-1.45-7.500.00--0.260.000.000.00
Cash from Financing Activities-147.88-132.61127.16-59.2544.02252.30-0.88-4.49223.36
Net Change in Cash89.53115.1287.11-35.34-424.42245.2179.4457.4232.41
Free Cash Flow18.0719.61-135.80-121.65-73.95-47.29-14.73-70.32-49.57
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow111.0571.10-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments164.14286.45311.64248.96265.71339.94
Short Term Receivables31.6325.7533.8575.6921.4217.88
Inventories0.000.000.000.000.000.00
Other Current Assets2.653.914.766.014.785.29
Total Current Assets198.43316.11350.25330.65291.91363.11
Net Property, Plant & Equipment11.6613.3213.8914.4915.0915.66
Total Investments and Advances0.000.000.007.7028.0043.02
Deferred Tax Assets135.66-----
Other Assets0.260.260.260.260.260.26
Total Assets346.01329.68364.39353.10335.25422.05
Short Term Debt Incl. Current Port. of LT Debt2.162.122.082.042.001.96
Accounts Payable4.397.523.872.893.336.12
Other Current Liabilities28.8032.0632.6733.1730.2035.95
Total Current Liabilities35.3541.7038.6238.1035.5344.04
Long Term Debt267.43275.24288.56344.41344.46344.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities29.02-----
Other Liabilities3.620.000.000.000.000.00
Total Liabilities335.42316.94327.19382.51379.98388.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.5912.7537.21-29.42-44.7334.02
Total Shareholders Equity10.5912.7537.21-29.42-44.7334.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.5912.7537.21-29.42-44.7334.02
Total Liabilities & Stockholders Equity346.01329.68364.39353.10335.25422.05
Book Value Per Share0.360.441.33-1.07-1.601.12
Tangible Book Value Per Share0.360.441.33-1.07-1.601.12
Full-Time Employees--104---
Price to Book Ratio135.8827.84-30.29-12.7613.225.33
Return on Assets70.78-7.13-3.12-19.99-34.77-33.97
Return on Equity--114.55-24.49-308.02--343.83
Return on Invested Capital66.14-18.3615.234.80-12.89-10.40
Quick Ratio5.617.589.078.688.228.25
Current Ratio5.617.589.078.688.228.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income274.60-52.8849.6115.11-38.63-39.33
Depreciation0.360.610.610.610.600.61
Other Funds (Non Cash)-82.0535.0727.8830.5427.2525.56
Funds from Operations9.22-17.2078.1046.27-10.78-13.16
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-35.86-8.7119.90-73.62-29.462.46
Cash from Operating Activities-26.64-25.9298.00-27.36-40.24-10.70
Capital Expenditures0.02-0.02-0.00-0.01-0.04-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.5435.0073.50103.2936.4414.88
Purchase of Investments-4.960.000.00-19.66-54.21-122.55
Sale Or Maturity of Investments12.5035.0073.50122.9590.65137.43
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.5634.9873.50103.2836.4014.85
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock11.3514.028.83-9.38-49.67-4.13
Repurchase of Common Pref Stock0.000.00-3.38-9.72-51.10-4.42
Sale of Common Pref Stock11.3514.0212.210.341.420.29
Proceedsfrom Stock Options11.3514.0212.210.341.420.29
Issuance or Reduction of Debt, Net-6.92-12.81-51.96-1.01-0.82-23.00
Change in Long Term Debt-6.92-12.81-51.96-1.01-0.82-23.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-6.92-12.81-51.96-1.01-0.82-23.00
Net Financing Active Other Cash Flow-100.000.000.000.000.00-1.45
Other Financing Activities Uses-100.000.000.000.000.00-1.45
Cash from Financing Activities-95.561.21-43.13-10.39-50.50-28.59
Net Change in Cash-114.6410.27128.3665.53-54.34-24.44
Free Cash Flow-26.62-25.9498.00-27.37-40.28-10.73
Price to Free Cash Flow111.05360.9077.49---

Revenue breakdown

Pharmaceutical Preparations2024: 91.28M 2025: 234.60M
United States2024: 91.28M 2025: 234.60M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.09%5.1M27.9M485.76K
2026-10-1519.31%5.4M27.9M538.26K
2026-09-3018.77%5.2M27.9M592.21K
2026-09-1519.49%5.4M27.9M587.94K
2026-08-3119.59%5.4M27.6M593.35K
2026-08-1419.31%5.3M27.5M619.16K
2026-07-3119.47%5.4M27.8M668.97K
2026-07-1518.02%5.0M27.8M694.93K
2026-06-3018.55%5.1M27.8M692.32K
2026-06-1517.01%4.6M27.2M763.00K
2026-05-2917.71%4.8M27.2M827.88K
2026-05-1517.61%4.8M27.2M826.09K
2026-04-3016.41%4.5M27.2M857.94K
2026-04-1515.29%4.1M26.9M787.47K
2026-03-3117.97%4.8M26.8M544.94K
2026-03-1317.91%4.8M26.8M490.23K
2026-02-2720.05%5.4M26.8M456.28K
2026-02-1321.84%5.6M25.8M515.71K
2026-01-3021.94%5.7M25.8M550.05K
2026-01-1521.56%5.6M25.8M542.76K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.000.000.0048.71-1.000.00---
call30.000.000.000.00-0.000.00---
call35.000.000.0011.97-3.000.00---
call40.000.000.007.60-3.000.00---
call45.000.000.004.50-14.000.00---
call50.000.000.001.80-13.000.00---
call55.000.000.001.00-1480.00---
call60.000.000.002.14-74.000.00---
call65.000.000.000.23-1890.00---
call70.000.000.003.40-28.000.00---
call75.000.000.003.55-78.000.00---
call80.000.000.000.05-2.000.00---
call85.000.000.009.00-0.000.00---
call90.000.000.002.00-2.000.00---
call95.000.000.001.85-21.000.00---
call1000.000.002.03-2.000.00---
call1050.000.001.00-1.000.00---
put25.000.000.000.90-12.000.00---
put30.000.000.000.63-2.000.00---
put35.000.000.000.30-1910.00---
put40.000.000.000.95-5110.00---
put45.000.000.002.00-63.000.00---
put50.000.000.005.70-15.000.00---
put55.000.000.006.60-17.000.00---
put60.000.000.0015.20-26.000.00---
put65.000.000.000.00-0.000.00---
put70.000.000.0015.65-0.000.00---
put75.000.000.0024.50-0.000.00---
put80.000.000.000.00-0.000.00---
put85.000.000.000.00-0.000.00---
put90.000.000.000.00-0.000.00---
put95.000.000.000.00-0.000.00---
put1000.000.000.00-0.000.00---
put1050.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-2110-KT2026-06-30SEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-03-12SEC
2026-08-074Statement of changes in beneficial ownership of securities2026-03-12SEC
2026-07-308-KCurrent report2026-07-28SEC
2026-07-13144Filing for proposed sale of securities under Rule 144.SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29ARSAnnual report to security holders. 2025-12-31SEC
2026-06-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-29SEC
2026-06-26144Filing for proposed sale of securities under Rule 144.SEC
2026-06-228-KCurrent report2026-06-15SEC
2026-06-17144Filing for proposed sale of securities under Rule 144.SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-16144Filing for proposed sale of securities under Rule 144.SEC
2026-06-15144Filing for proposed sale of securities under Rule 144.SEC
2026-06-12144Filing for proposed sale of securities under Rule 144.SEC
2026-06-11144Filing for proposed sale of securities under Rule 144.SEC
2026-06-10144Filing for proposed sale of securities under Rule 144.SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-08144Filing for proposed sale of securities under Rule 144.SEC
2026-06-05144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000249.37K1
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03002.25M2
2026-0200540.00K1
2026-01003.70M13
2025-12003.01M8
2025-110000

Institutional holders

Manager% owned
EcoR1 Capital, LLC27.08%
BlackRock, Inc.6.34%
TANG CAPITAL MANAGEMENT LLC4.57%
STATE STREET CORP4.42%
VANGUARD CAPITAL MANAGEMENT LLC3.11%
Affinity Asset Advisors, LLC2.84%
MILLENNIUM MANAGEMENT LLC2.77%
Sanofi2.75%
Woodline Partners LP2.46%
683 Capital Management, LLC2.27%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF2.70%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.23%
iShares Russell 2000 ETF1.77%
Nuveen Quant Small Cap Equity Fund0.89%
VANGUARD EXTENDED MARKET INDEX FUND0.81%
Fidelity Small Cap Index Fund0.73%
Federated Hermes Kaufmann Small Cap Fund0.71%
iShares Biotechnology ETF0.67%
iShares Russell 2000 Growth ETF0.64%
Victory Science & Technology Fund0.63%

OakChart. ANAB. Cached 15 minutes.